Baxter Reports European Launch Of NUMETA G13E 300mL Nutrition Product

(RTTNews) - Baxter International Inc. (BAX) announced the European launch of NUMETA G13E 300 mL, the only ready-to-use parenteral (intravenous) nutrition product available to treat preterm infants (less than 37 weeks gestation age). NUMETA G13E is indicated for PN administration in preterm newborn infants when oral or enteral nutrition is not possible, insufficient or contraindicated.

Baxter's NUMETA G13E has Marketing Authorization from the Competent Authorities in 15 Western European countries. Baxter plans to continue pursuing regulatory approvals and launching NUMETA G13E globally, including in additional European countries and Latin America in 2017.